A Phase I Dose-Escalation Study of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors
A Phase I, First-In-Human, Open-Label, Multicenter, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors
CUG279-P101 is a first-in-human, open-label, multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, immune-pharmacodynamics, and preliminary antitumor activity of CUG279 in adults with select unresectable advanced or metastatic solid tumors.
調査の概要
詳細な説明
The study will consist of two parts: Part A Dose Escalation and Part B Dose Expansion
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Admin Cugene
- 電話番号:1(781) 893-5800
- メール:admin@cugene.com
研究場所
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 募集
- NEXT Virginia
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Signed and dated informed consent.
- Histologically or cytologically confirmed selected locally advanced or metastatic solid tumor.
- At least 1 measurable lesion according to RECIST v1.1.
- Progressed after, intolerant to, declined, or not considered a candidate for available standard-of-care (SoC) therapy.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Adequate cardiovascular, hematologic, renal, hepatic, and coagulation function.
- Life expectancy of ≥3 months.
- Female participants must not be pregnant or breastfeeding. Male participants with female partners of childbearing potential must agree to use effective contraception as specified in the protocol.
Exclusion Criteria
- Rapidly progressing disease or disease requiring urgent alternative medical intervention.
- Recent or concurrent malignancy, except certain adequately treated or low-risk malignancies as specified in the protocol.
- Prior anticancer, investigational, radiation, or immunomodulatory therapy within protocol-specified washout periods, or prior IL-2/IL-15-based therapy.
- Concurrent participation in another interventional therapeutic clinical trial.
- Active or clinically significant CNS disease, including symptomatic CNS metastases or leptomeningeal disease, except as specified in the protocol.
- Clinically significant autoimmune disease, immunodeficiency, requirement for systemic immunosuppressive therapy, or history of severe immune-mediated adverse events.
- Unresolved clinically significant toxicities from prior anticancer therapy.
- Clinically significant cardiovascular, thromboembolic, pulmonary, hepatic, or gastrointestinal disease.
- Active or clinically significant infection except as specified in the protocol.
- Recent major surgery or trauma, or prior allogeneic hematopoietic stem cell, bone marrow, or solid organ transplantation.
- Known hypersensitivity or significant allergic reaction to biologics or its components.
- Recent vaccination, except as permitted by the protocol.
- Any medical, psychological, social, or other condition that, in the Investigator's opinion, may increase risk, interfere with study participation, or confound interpretation of study results
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part A Dose Escalation
CUG279 will be administered at multiple ascending dose levels |
CUG279 will be administered intravenously according to the protocol |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of dose limiting toxicities (DLTs)
時間枠:From the first dose up to 21 days post-dose
|
The number and percentage of participants with DLTs will be assessed according to the protocol-specified DLT criteria in Part A. |
From the first dose up to 21 days post-dose
|
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
時間枠:From first dose through 90 days after the last dose
|
The number and percentage of participants with TEAEs will be assessed. AEs will be graded according to NCI-CTCAE Version 6.0. |
From first dose through 90 days after the last dose
|
|
Incidence of serious adverse events (SAEs)
時間枠:From first dose through 90 days after the last dose
|
The number and percentage of participants with SAEs will be assessed. |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in safety laboratory parameters from baseline
時間枠:From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in safety laboratory parameters will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0 |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in electrocardiogram (ECG) findings from baseline
時間枠:From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in ECGs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0 |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in vital signs from baseline
時間枠:From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in vital signs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0. |
From first dose through 90 days after the last dose
|
|
Incidence of TEAEs leading to dose modifications
時間枠:From the first dose through the last dose; up to 1 year
|
The number and percentage of participants with TEAEs leading to CUG279 dose modification will be assessed. |
From the first dose through the last dose; up to 1 year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum observed plasma concentration (Cmax) of CUG279
時間枠:From first dose through 90 days after the last dose
|
The maximum observed plasma concentration (Cmax) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Trough plasma concentrations (Ctrough) of CUG279
時間枠:From first dose through 90 days after the last dose
|
The trough plasma concentration (Ctrough) of CUG279 will be determined from plasma samples collected immediately before the next scheduled dose |
From first dose through 90 days after the last dose
|
|
Area under the concentration-time curve (AUC) of CUG279
時間枠:From first dose through 90 days after the last dose
|
The area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-last) of CUG279 will be calculated using plasma concentration-time data. |
From first dose through 90 days after the last dose
|
|
Terminal half-life (T1/2) of CUG279
時間枠:From first dose through 90 days after the last dose
|
The terminal elimination half-life (t½) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Systemic clearance (CL) of CUG279
時間枠:From first dose through 90 days after the last dose
|
The systemic clearance (CL) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Volume of distribution (Vz) of CUG279
時間枠:From first dose through 90 days after the last dose
|
The volume of distribution (Vz) of CUG279 will be determined from plasma concentration-time data. |
From first dose through 90 days after the last dose
|
|
Incidence of anti-CUG279 antibodies (ADA)
時間枠:From first dose through 90 days after the last dose
|
Number and percentage of participants with treatment-emergent or treatment-enhanced anti-CUG279 antibodies will be determined. |
From first dose through 90 days after the last dose
|
|
Incidence of anti-CUG279 neutralizing antibodies (NAb)
時間枠:From first dose through 90 days after the last dose
|
Number and percentage of participants with neutralizing anti-CUG279 antibodies will be determined |
From first dose through 90 days after the last dose
|
|
Objective response rate (ORR)
時間枠:From the first dose through study completion or until disease progression; up to 1 year
|
Percentage of participants whose best overall response is a confirmed complete response (CR) or partial response (PR) will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Disease control rate (DCR)
時間枠:From the first dose through study completion or until disease progression; up to 1 year
|
Percentage of participants whose best overall response is CR, PR, or stable disease (SD) will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Time to response (TTR)
時間枠:From the first dose through study completion or until disease progression; up to 1 year
|
Time from the first dose of CUG279 to the first documented CR or PR will be determined, per RECIST v1.1 |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Duration of response (DoR)
時間枠:From the first dose through study completion or until disease progression; up to 1 year
|
Time from first documented CR or PR to disease progression will be determined per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Best overall response (BOR)
時間枠:From the first dose through study completion or until disease progression; up to 1 year
|
Best confirmed overall tumor response recorded from the first dose until disease progression or the end of efficacy assessment will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Progression-free survival (PFS)
時間枠:From the first dose through study completion or until disease progression; up to 1 year
|
Time from the first dose of CUG279 to radiographic disease progression will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。